Bayer's hemophilia type A treatment Jivi has been approved for domestic items. The MFDS recently granted Jivi to routine prophylaxis for on-demand and suppression of bleeding episodes in adults and adolescents (blood coagulation factor VIII birth deficiency) who have been treated before, management of bleeding before and after surgery, and reducing the frequency of bleeding episodes.

Jivi obtained permission from the EU Commission in November of the same year after being approved by the U.S. FDA as a routine preventive treatment for youth and adult hemophilia patients aged 12 and older with a history of treatment in August 2018.

Since t1/2 is maintained at 17.9 hours, the initial recomme